March 18, 2024
Via: PMLiVEThe authorisation specifically applies to adult patients with unresectable or metastatic ESCC after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Oesophageal cancer is the sixth most common cause of cancer-related deaths globally and ESCC accounts for almost […]
January 23, 2023
Via: PMLiVEThe FDA’s decision was based on two global head-to-head phase 3 clinical trials in which Brukinsa – a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) – demonstrated superior efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or […]
Cell and Gene Therapy, Industry
June 9, 2021
Via: Biopharma DiveBeigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several […]
July 19, 2024
July 11, 2024
July 11, 2024
Copyright © 2024. All rights reserved
